Autopsy report · NCT06128044

CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia

“Sponsor Decision - Pipeline Reprioritization”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 months before it started.
• Ran for about 1 year 4 months before it stopped.
• 12 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Caribou Biosciences, Inc.

Sponsor type

Industry

Conditions

Acute Myeloid Leukemia, in Relapse; Acute Myeloid Leukemia Refractory

Interventions

CB-012

Participants

12

Sites

10

Countries

United States

Trials that died the same way

• Non-alcoholic Steatohepatitis Registry Platform Study
  “Following a reassessment of the company's pipeline priorities, the sponsor has elected to discontinue this project prior to its planned completion” (74% match in meaning)
• A Biomarker Screening Protocol for Participants With Solid Tumors
  “Pipeline Reprioritization” (68% match in meaning)
• Impact of Bridge™ Device to Treat Opioid Withdrawal Symptoms
  “Sponsor Decision” (66% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.